Cargando…

Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction

A limited number of studies have explored whether the role of circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathogenesis of acute myocardial infarction (AMI) is sex specific. The purpose of the present study was to examine sex differences in plasma PCSK9 in Chinese patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhong, Wei, Teng-Fei, Zhao, Bei, Yin, Zhao, Shi, Quan-Xing, Liu, Pei-Lin, Liu, Li-Feng, Liu, Li, Zhao, Jing-Tao, Mao, Shuai, Rao, Meng-Meng, Wang, Shou-Li, Chen, Yun-Dai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395605/ https://www.ncbi.nlm.nih.gov/pubmed/30816133 http://dx.doi.org/10.1038/s41598-018-35773-x

Ejemplares similares

Circulating PCSK9 and Risk of Myocardial Infarction: The HUNT Study in Norway
por: Laugsand, Lars E., et al.
Publicado: (2016)

Sex difference in circulating PCSK9 and its clinical implications
por: Jia, Fang, et al.
Publicado: (2022)

Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction
por: Gao, Jing, et al.
Publicado: (2021)

PCSK9 Modulates Macrophage Polarization-Mediated Ventricular Remodeling after Myocardial Infarction
por: Wang, Feifei, et al.
Publicado: (2022)

PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
por: Andreadou, Ioanna, et al.
Publicado: (2020)

In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction
por: Lou, Bowen, et al.
Publicado: (2022)

Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy
por: Ma, Yu, et al.
Publicado: (2022)

The predictive utility of circulating PCSK9 levels on diabetes mellitus
por: Peng, Jia, et al.
Publicado: (2021)

Lipid Lowering Therapy and Circulating PCSK9 Concentration
por: Nozue, Tsuyoshi
Publicado: (2017)

Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
por: Azar, Yara, et al.
Publicado: (2022)

PCSK9 inhibition potentiates cancer immune checkpoint therapy
por: Liu, Xinjian, et al.
Publicado: (2020)

Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies
por: Almontashiri, Naif A. M., et al.
Publicado: (2014)

Incomplete protective effect of coronary collateral circulation for acute myocardial infarction patients
por: Liu, Ruifeng, et al.
Publicado: (2020)

Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
por: Cao, Ye-Xuan, et al.
Publicado: (2019)

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
por: Lagace, Thomas A.
Publicado: (2014)

The circulating furin-cleaved/mature PCSK9 ratio has a potential prognostic significance in statin-naïve patients with acute ST elevation myocardial infarction
por: Sawaguchi, Jun, et al.
Publicado: (2022)

Circulating MicroRNA-145 is Associated with Acute Myocardial Infarction and Heart Failure
por: Zhang, Ming, et al.
Publicado: (2017)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
por: Schreckenberg, Rolf, et al.
Publicado: (2022)

PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction
por: Puteri, Meidi Utami, et al.
Publicado: (2022)

PCSK9 and Other Metabolic Targets to Counteract Ischemia/Reperfusion Injury in Acute Myocardial Infarction and Visceral Vascular Surgery
por: Ortona, Silvia, et al.
Publicado: (2022)

Increased half-life and enhanced potency of Fc-modified human PCSK9 monoclonal antibodies in primates
por: Shen, Yijun, et al.
Publicado: (2017)

Effect of Triglyceride-Glucose Indices and Circulating PCSK9-Associated Cardiovascular Risk in STEMI Patients with Primary Percutaneous Coronary Artery Disease: A Prospective Cohort Study
por: Zhao, Xiaoxiao, et al.
Publicado: (2023)

Differential expression of circulating long non-coding RNAs in patients with acute myocardial infarction
por: Zhong, Zhixiong, et al.
Publicado: (2018)

Correlation Between Circulating PCSK9 Levels and Gestational Diabetes Mellitus in a Chinese Population
por: Wu, Yiming, et al.
Publicado: (2022)

Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population
por: Guo, Wen, et al.
Publicado: (2018)

Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study)
por: LIU, Yu-Qi, et al.
Publicado: (2021)

Blood lipid-related low-frequency variants in LDLR and PCSK9 are associated with onset age and risk of myocardial infarction in Japanese
por: Tajima, Tomoyuki, et al.
Publicado: (2018)

Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction
por: Ueland, Thor, et al.
Publicado: (2018)

Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study
por: Miñana, Gema, et al.
Publicado: (2020)

Circulating Total Bilirubin and Long-Term Prognosis in Patients With Previous Myocardial Infarction
por: Cao, Ye-Xuan, et al.
Publicado: (2023)

Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
por: Hwang, Hyeon Seok, et al.
Publicado: (2020)

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
por: Kuyama, Naoto, et al.
Publicado: (2021)

Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis—The IMPROVE Study
por: Coggi, Daniela, et al.
Publicado: (2021)

Autocrine effects of PCSK9 on cardiomyocytes
por: Wolf, Annemarie, et al.
Publicado: (2020)

Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials
por: Cao, Ye-Xuan, et al.
Publicado: (2018)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
por: Cai, Gaojun, et al.
Publicado: (2018)

Prognostic Value of Circulating MG53 Levels in Acute Myocardial Infarction
por: Xie, Hongyang, et al.
Publicado: (2020)

PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma
por: Zhang, Shi-Zhe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ltmoldd32uobsj4e12eqjjatr9